EFFICACY OF THE COMBINATION OF BUDESONIDE, GLYCOPYRRONIUM, AND FORMOTEROL IN THE TREATMENT OF COPD

Abstract

Budesonide/glycopyrronium/formoterol (BUD/GLY/FORM) is an inhaled fixed-dose combination of the inhaled corticosteroid (ICS), the long-acting muscarinic antagonist (LAMA) and the long-acting β2 agonist (LABA) approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). BUD/GLY/FORM reduced the rates of moderate and severe COPD exacerbations, improved lung function to a greater extent than BUD/FORM and (or) GLY/FORM, demonstrated beneficial effects on dyspnoea and health-related quality of life. BUD/GLY/FORM reduced the risk of all-cause mortality. BUD/GLYI/FORM was well tolerated, with the tolerability profile being similar to that of the individual components. BUD/GLY/FORM provides an effective and convenient option for the maintenance treatment of COPD for patients whose disease is inadequately controlled with dual ICS/LABA or LAMA/LABA therapy.